Drug intelligence / Profile preview

Marburg virus vaccine candidate

Development stage: Preclinical
Lead developer: International AIDS Vaccine Initiative
Modality: Vaccines & Immunotherapeutics
Administration: Intramuscular, Intranasal

Overview

IAVI is developing a Marburg virus vaccine candidate utilizing its recombinant vesicular stomatitis virus (rVSV) platform. This vaccine development effort is supported financially by the Biomedical Advanced Research and Development Authority (BARDA) and the Defense Threat Reduction Agency (DTRA) of the U.S. Department of Defense. The rVSV platform, licensed from the Public Health Agency of Canada (PHAC), serves as the basis for several of IAVI's vaccine programs, including those against HIV, Lassa Fever, Sudan ebolavirus, and COVID-19.

Targets

VP40 (Ebola virus matrix protein VP40)

Beyond the preview

Go deeper on Marburg virus vaccine candidate.

Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.

Clinical trials

Follow clinical development from study design and recruitment through results.

Trial phase
Status
Readouts

Indications & development

Explore development by indication, patient population, and geography.

Indications
Development status
Countries

Licensing & deals

Trace asset ownership, licensing agreements, and commercial partnerships.

Partners
Deal terms
Milestones

Patents & exclusivity

Explore the patent landscape and regulatory exclusivity around an asset.

Patents
Expiration dates
Exclusivity

Competitive landscape

Compare development programs by target, modality, and indication.

Competing assets
Targets
Development stage

Research & analysis

Connect source evidence and development news to your research questions.

Publications
News
Analysis

Bring the full picture into focus.

See how Gosset can support your research on Marburg virus vaccine candidate.

Explore the full profile